Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA. The post Could buying this gene-editing penny stock at $1 make me ...

Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the Vanguard Mega Cap ETF (MGC), a passively managed exchange traded fund launched on 12/17/2007.